KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $2.5 billion.

  • Eli Lilly's Capital Expenditures rose 7021.12% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.8 billion, marking a year-over-year increase of 5502.17%. This contributed to the annual value of $7.8 billion for FY2025, which is 5502.17% up from last year.
  • Latest data reveals that Eli Lilly reported Capital Expenditures of $2.5 billion as of Q4 2025, which was up 7021.12% from $2.1 billion recorded in Q3 2025.
  • Eli Lilly's Capital Expenditures' 5-year high stood at $2.5 billion during Q4 2025, with a 5-year trough of $291.4 million in Q4 2021.
  • Over the past 5 years, Eli Lilly's median Capital Expenditures value was $854.2 million (recorded in 2023), while the average stood at $975.6 million.
  • Per our database at Business Quant, Eli Lilly's Capital Expenditures plummeted by 3591.38% in 2021 and then surged by 11390.05% in 2023.
  • Eli Lilly's Capital Expenditures (Quarter) stood at $291.4 million in 2021, then soared by 71.83% to $500.7 million in 2022, then surged by 113.9% to $1.1 billion in 2023, then surged by 39.7% to $1.5 billion in 2024, then surged by 70.21% to $2.5 billion in 2025.
  • Its Capital Expenditures was $2.5 billion in Q4 2025, compared to $2.1 billion in Q3 2025 and $1.7 billion in Q2 2025.